Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin.59, 225–249 (2009).
   PubMed Web of Science ®Google Scholar
• Cardoso F, Bedard PL, Winer EP et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J. Natl Cancer Inst.101, 1174–1181 (2009).
   PubMedGoogle Scholar
• Robinson DM, Keating GM. Albumin-bound paclitaxel: in metastatic breast cancer. Drugs66, 941–948 (2006).
   PubMed Web of Science ®Google Scholar
• Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J. Natl Cancer Inst.83, 288–291 (1991).
   PubMed Web of Science ®Google Scholar
• Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol. Oncol. Clin. North Am.21, 257–272 (2007).
   PubMed Web of Science ®Google Scholar
• Jones SE, Erban J, Overmoyer B et al. Randomized Phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol.23, 5542–5551 (2005).
   PubMed Web of Science ®Google Scholar
• Seidman AD, Berry D, Cirrincione C et al. Randomized Phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J. Clin. Oncol.26, 1642–1649 (2008).
   PubMed Web of Science ®Google Scholar
• Sparano JA, Wang M, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N. Engl. J. Med.358, 1663–1671 (2008).
   PubMed Web of Science ®Google Scholar
• Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br. J. Cancer93, 293–301 (2005).
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Burzykowski T, Buyse M et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J. Clin. Oncol.26, 1980–1986 (2008).
   PubMed Web of Science ®Google Scholar
• Albain KS, Nag SM, Calderillo-Ruiz G et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J. Clin. Oncol.26, 3950–3957 (2008).
   PubMed Web of Science ®Google Scholar
• Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann. Oncol.20, 449–453 (2009).
   PubMed Web of Science ®Google Scholar
• Moreno-Aspitia A, Perez EA. North Central Cancer Treatment Group N0531: Phase II trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. Clin. Breast Cancer6, 361–364 (2005).
   PubMedGoogle Scholar
• Lobo C, Lopes G, Silva O, Glück S. Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute. Biomed. Pharmacother.61, 531–533 (2007).
   PubMed Web of Science ®Google Scholar
• Gudena V, Montero AJ, Glück S. Gemcitabine and taxanes in metastatic breast cancer: a systematic review. Ther. Clin. Risk Manag.4(6), 1157–1164 (2008).
   PubMedGoogle Scholar
• Brouwer E, Verweij J, De Bruijn P et al. Measurement of fraction unbound paclitaxel in human plasma. Drug Metab. Dispos.28, 1141–1145 (2000).
   PubMed Web of Science ®Google Scholar
• Taxol®, package insert. Bristol-Myers Squibb Company, Princeton, NJ, USA.
   Google Scholar
• Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL. The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer37, 1590–1598 (2001).
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Desai N, Legha S et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res.8, 1038–1044 (2002).
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res.12, 1317–1324 (2006).
   PubMed Web of Science ®Google Scholar
• Teng XY, Guan ZZ, Yao ZW et al. [A tolerability study of a cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor]. Ai Zheng23, 1431–1436 (2004).
   PubMedGoogle Scholar
• Nyman DW, Campbell KJ, Hersh E et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clin. Oncol.23, 7785–7793 (2005).
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE, Socinski MA, Lee CB et al. Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies. J. Thorac. Oncol.3, 521–526 (2008).
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol.23, 7794–7803 (2005).
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Krasnojon D, Cheporov S et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J. Clin. Oncol.27, 3611–3619 (2009).
   PubMed Web of Science ®Google Scholar
• Blum JL, Savin MA, Edelman G et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin. Breast Cancer7, 850–856 (2007).
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Samuels B, Page R et al. Multicenter Phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J. Clin. Oncol.23, 6019–6026 (2005).
   PubMed Web of Science ®Google Scholar
• Lobo C, Lopes G, Glück S et al. Final results of a Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res. Treat.123(2), 427–435 (2010).
   PubMed Web of Science ®Google Scholar
• Abraxane®, package insert. Abraxis BioScience, Inc., Los Angeles, CA, USA.
   Google Scholar